PPS Shows Significant Pain Benefit in Rest of World Analysis
Filed with ASX · · 8 pages · English
Summary by 6ix AI
The analysis included participants from Australia, Hong Kong, and Moldova, revealing a notable reduction in average daily pain and enhanced physical function. The company is currently assessing the implications of these findings and exploring options for the continued development of its treatment, iPPS, following an interim futility result in the US.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
• Further analysis identifies significant pain relief outside the US. Following the overall interim futility result and findings in the US data, Paradigm investigated whether the result was consistent across regions. Analysis of 16 sites in Australia, Hong Kong and Moldova, collectively the rest of world (ROW), showed statistically significant improvement in weekly average daily pain (wADP) with i
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Expiry of PAROB Listed Options
- Notification of cessation of securities - PAR
- Update on Data Review and Convertible note redemption
- Continuation of Suspension from Quotation
- Appointment of Voluntary Administrators
Later from Paradigm Biopharmaceuticals
- Further Agreed Convertible Note Redemption
- Extension of Convening Period
- Deferral of AGM and Financial Reporting Obligations
- Convening Period Extended to 27 January 2027
- September 2026 Quarterly Activities Report & Appendix 4C
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals